Insiders Trades

★ Sign in to follow

MR

Matthew R. Henn

US·SEC (Form 4)

Seres Therapeutics, Inc.

Insider activity · 24 months0 buys2 salesCumulative net flow

Nov 24 · 0 buys · 1 saleDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 1 saleSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

27

Company

1

▲ Purchases (0 ops.)

—

▼ Sales (10 ops.)

€2.1M

Latest filing published 18 Aug 2026 for Seres Therapeutics, Inc..

Filing timeline

BuySale

Matthew R. Henn

Insider track record

Disclosed buys

0

Disclosed sells

10

Signal history

Matthew R. Henn: trading record in brief

All filings by Matthew R. Henn on record concern Seres Therapeutics, Inc. Between 26 January 2020 and 17 August 2026, the trades on record add up to 27 filings.

Sales make up the whole of the open-market record (10 sales, €2.1M). Besides market trades, the filings include 1 share grant and 16 option exercises. Since January 2026: no purchases and 1 sale on the market.

The latest filing, published on 18 August 2026, reports an option exercise in Seres Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.

Companies and markets linked to Matthew R. Henn

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Seres Therapeutics, Inc. (US)

Declarations27 total

◇

Matthew R. Henn

See RemarksExecutives15 Aug 2026Seres Therapeutics, Inc.

0SEC

238 sharesCommon StockSEC:0001193125-26-355718:0

▼

Matthew R. Henn

See RemarksExecutives17 Aug 2026Seres Therapeutics, Inc.

369 USD31SEC

81 shares@ US$4.550.0010% mcap100.0% of flowCommon StockSEC:0001193125-26-355718:1

◇

Matthew R. Henn

See RemarksExecutives15 Feb 2026Seres Therapeutics, Inc.

0SEC

239 sharesCommon StockSEC:0001193125-26-057153:0

◇

Matthew R. Henn

See RemarksExecutives15 Nov 2025Seres Therapeutics, Inc.

0SEC

3,998 sharesCommon StockSEC:0001193125-25-286226:0

◇

Matthew R. Henn

See RemarksExecutives15 Aug 2025Seres Therapeutics, Inc.

0SEC

141 sharesCommon StockSEC:0000950170-25-110090:0

◇

Matthew R. Henn

See RemarksExecutives15 May 2025Seres Therapeutics, Inc.

0SEC

140 sharesCommon StockSEC:0000950170-25-074323:0

◇

Matthew R. Henn

See RemarksExecutives15 Feb 2025Seres Therapeutics, Inc.

0SEC

2,813 sharesCommon StockSEC:0000950170-25-023580:0

▼

Matthew R. Henn

See RemarksExecutives18 Nov 2024Seres Therapeutics, Inc.

501 USD0SEC

927 shares@ US$0.5407Common StockSEC:0000950170-24-128611:1

◇

Matthew R. Henn

See RemarksExecutives15 Nov 2024Seres Therapeutics, Inc.

0SEC

2,812 sharesCommon StockSEC:0000950170-24-128611:0

▼

Matthew R. Henn

See RemarksExecutives28 Oct 2024Seres Therapeutics, Inc.

2,749 USD0SEC

3,984 shares@ US$0.6901Common StockSEC:0000950170-24-118418:1

◇

Matthew R. Henn

See RemarksExecutives27 Oct 2024Seres Therapeutics, Inc.

0SEC

12,622 shares0Common StockSEC:0000950170-24-118418:0

▼

Matthew R. Henn

See RemarksExecutives16 Aug 2024Seres Therapeutics, Inc.

775 USD0SEC

923 shares@ US$0.84Common StockSEC:0000950170-24-098715:1

◇

Matthew R. Henn

See RemarksExecutives15 Aug 2024Seres Therapeutics, Inc.

0SEC

2,813 sharesCommon StockSEC:0000950170-24-098715:0

▼

Matthew R. Henn

See RemarksExecutives15 May 2024Seres Therapeutics, Inc.

838 USD0SEC

891 shares@ US$0.94Common StockSEC:0000950170-24-062057:1

◇

Matthew R. Henn

See RemarksExecutives15 May 2024Seres Therapeutics, Inc.

0SEC

2,812 sharesCommon StockSEC:0000950170-24-062057:0

▼

Matthew R. Henn

See RemarksExecutives16 Feb 2024Seres Therapeutics, Inc.

4,504 USD0SEC

4,170 shares@ US$1.08Common StockSEC:0000950170-24-016695:1

◇

Matthew R. Henn

See RemarksExecutives15 Feb 2024Seres Therapeutics, Inc.

0SEC

11,250 sharesCommon StockSEC:0000950170-24-016695:0

▼

Matthew R. Henn

See RemarksExecutives30 Oct 2023Seres Therapeutics, Inc.

5,246 USD0SEC

3,886 shares@ US$1.35Common StockSEC:0000899243-23-020069:1

◇

Matthew R. Henn

See RemarksExecutives27 Oct 2023Seres Therapeutics, Inc.

0SEC

12,623 shares0Common StockSEC:0000899243-23-020069:0

◆

Matthew R. Henn

See RemarksExecutives5 Jul 2022Seres Therapeutics, Inc.

150,000 USD10SEC

47,619 shares@ US$3.15100.0% of flowCOMMON STOCKSEC:0000899243-22-025520:0

◇

Matthew R. Henn

See RemarksExecutives1 Dec 2020Seres Therapeutics, Inc.

18,460 USD2SEC

26,000 shares@ US$0.710.6% of flowCommon StockSEC:0000899243-20-032667:0

◇

Matthew R. Henn

See RemarksExecutives1 Dec 2020Seres Therapeutics, Inc.

259,613 USD3SEC

26,250 shares@ US$9.898.4% of flowCommon StockSEC:0000899243-20-032667:1

◇

Matthew R. Henn

See RemarksExecutives1 Dec 2020Seres Therapeutics, Inc.

165,648 USD3SEC

27,562 shares@ US$6.015.3% of flowCommon StockSEC:0000899243-20-032667:2

▼

Matthew R. Henn

See RemarksExecutives1 Dec 2020Seres Therapeutics, Inc.

1M USD7SEC

55,706 shares@ US$26.5647.7% of flowCommon StockSEC:0000899243-20-032667:3

▼

Matthew R. Henn

See RemarksExecutives1 Dec 2020Seres Therapeutics, Inc.

723,863 USD4SEC

26,265 shares@ US$27.5623.3% of flowCommon StockSEC:0000899243-20-032667:4

25 of 27 declarations